Barclays Upgrades Certara (NASDAQ:CERT) to “Overweight”

Certara (NASDAQ:CERT) was upgraded by analysts at Barclays from an “equal weight” rating to an “overweight” rating in a report issued on Thursday, MarketBeat.com reports. The firm presently has a $14.00 target price on the stock, up from their previous target price of $11.00. Barclays‘s price target points to a potential upside of 16.86% from the company’s current price.

A number of other analysts have also issued reports on CERT. Robert W. Baird raised their price target on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. JMP Securities restated a “market perform” rating on shares of Certara in a report on Tuesday. KeyCorp upped their price target on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. Stephens reiterated an “overweight” rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.67.

Certara Stock Performance

NASDAQ:CERT opened at $11.98 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market cap of $1.94 billion, a PE ratio of -59.90, a P/E/G ratio of 9.29 and a beta of 1.57. The firm has a 50 day simple moving average of $11.67 and a 200-day simple moving average of $11.67. Certara has a 1-year low of $8.64 and a 1-year high of $17.76.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS. On average, equities analysts expect that Certara will post 0.28 EPS for the current year.

Institutional Trading of Certara

A number of institutional investors have recently added to or reduced their stakes in CERT. Barclays PLC lifted its stake in shares of Certara by 198.3% during the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after purchasing an additional 46,880 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after buying an additional 6,868 shares during the period. Kopion Asset Management LLC lifted its position in Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock worth $5,918,000 after acquiring an additional 175,005 shares in the last quarter. Blue Trust Inc. boosted its holdings in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares during the period. Finally, KBC Group NV grew its position in Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after acquiring an additional 3,125 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.